KDL Biotech Ltd.
|BSE: 532291||Sector: Health care|
|NSE: KOPDRUGS||ISIN Code: INE746A01010|
|BSE 00:00 | 02 Mar||KDL Biotech Ltd|
|NSE 05:30 | 01 Jan||KDL Biotech Ltd|
KDL Biotech Ltd. (KOPDRUGS) - News Sector
9.34 pm | 14 Nov 2018 | Business Standard
Analysts cut earnings estimates on muted India business growth outlook, rising expenses on specialty launches in the US
9.22 pm | 14 Nov 2018 | Business Standard
Targets Rs 100 billion revenue in the next five years
5.40 pm | 14 Nov 2018 | Press Trust of India
The company's board approved a scheme of arrangement between Apollo Hospitals Enterprise and Apollo Pharmacies Ltd
4.30 pm | 14 Nov 2018 | Press Trust of India
Revenue from operations of the company stood at Rs 5.19 billion in the quarter
11.56 am | 14 Nov 2018 | Business Standard
The stock was down 5 per cent at Rs 533, trading at its lowest level since July 17, 2018, on BSE.
8.28 am | 14 Nov 2018 | Business Standard
Acquisition to help the company build a specialty pipeline in the US
1.37 am | 14 Nov 2018 | Business Standard
The board also approved the allotment of Rs 230 million equity shares through preferential issue to Northern TK Ventures
1.25 am | 14 Nov 2018 | Business Standard
Company misses revenue estimates too, delivering a top line of Rs 69.37 bn, up a moderate 4.3%. Analysts had expected double-digit revenue growth for ...
11.45 pm | 13 Nov 2018 | Business Standard
Domestic growth is likely to remain firm going ahead, while US growth led by new launches and speciality products should drive earnings
5.47 pm | 13 Nov 2018 | Press Trust of India
The board of Fortis has also approved the appointment of four IHH nominees on the company's board
5.39 pm | 13 Nov 2018 | Business Standard
The senior management of Aurobindo said they are looking at launching the Oncology products in the US market by the end of this year
11.14 am | 13 Nov 2018 | Business Standard
The company reported a 21.7 per cent decline in net profit at Rs 6.11 billion for the quarter ended September 2018, owing to rise in costs.
8.53 am | 13 Nov 2018 | Business Standard
Here's a look at the top stocks that may remain in focus in today's trade -
9.12 pm | 12 Nov 2018 | Business Standard
The company was able to improve its US formulations revenues by 6.1 per cent year-on-year at Rs 22.27 billion.
1.51 am | 12 Nov 2018 | Business Standard
The Fortis stock has seen an erosion of 5.4% since the deal was announced in mid-July
10.39 pm | 10 Nov 2018 | Business Standard
Vinay Kumar, a chronic diabetic living on the insulin pump, is helping early detection and complete management of diabetes through his novel invention...
4.59 pm | 9 Nov 2018 | Business Standard
The company has proposed to buy a minimum number of 1.25 million shares from the open market route in the six-month period
11.30 pm | 8 Nov 2018 | Business Standard
Sources indicated the resignation comes in at a time when the management control of the firm is changing and the new promoters are unlikely to have 'l...
8.53 pm | 8 Nov 2018 | Reuters
It is the first quarter of sustainable product sales growth since 2014 and shares in the group, which staved off a takeover bid from Pfizer four years...
7.16 pm | 8 Nov 2018 | Business Standard
Domestic market has contributed a third of Natco Pharma's revenues of Rs 22 billion in 2017-18, though slipped in sales for the first time